Lymphangioleiomyomatosis--a brief review and estimation of excess risk
Related Experiment Video
Updated: May 24, 2026

07:36
Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
Published on: May 1, 2015
1Samsung Life Service Co. 10th Fl. Samsung-Jeil Bldg, 702-2, Yeoksam-Dong, Gangnam-Gu, Seoul, Korea, 135-751. sinhyung.lee@samsung.com
Journal of Insurance Medicine (New York, N.Y.)
|March 9, 2012
Abstract:
Lymphangioleiomyomatosis (LAM) is a rare pulmonary disease in women of child-bearing age. It is multisystem disease and affects mainly the lungs. A recently published Korean medical article showed a sharp increase of LAM patients in Korea since 2004. LAM is not discussed in the standard textbook of insurance medicine. This article will briefly review LAM and estimate excess risk derived from recently published articles.
